Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06841913 · ClinicalTrials.gov registry record · Phase 4
Woodsmoke Exposure, Influenza Infection, and Nasal Immunity
A Phase 4 study, sponsored by University of North Carolina, Chapel Hill.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 112
- Enrollment target
NCT06841913 is a Phase 4 study that is actively recruiting participants, run by University of North Carolina, Chapel Hill. The registered enrollment target is 112 participants.
The verdict
NCT06841913, a Phase 4 study, is actively recruiting participants, sponsored by University of North Carolina, Chapel Hill.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 112 participants
- Enrollment target
Study Summary
This study will investigate the effects of woodsmoke (WS) exposure on human nasal mucosal immune responses to viral infection. The study tests the hypotheses that WS exposure modifies biomarkers of nasal mucosal immune function, increases in Live Attenuated Influenza Virus (LAIV) -induced nasal symptoms, and reduces mucosal antibody production.
Interventions
- BIOLOGICAL LAIV nasal vaccine is chosen as a model viral infection
- OTHER Wood smoke
- BIOLOGICAL Placebo for LAIV nasal vaccine is chosen as a model viral infection
- OTHER Placebo for Wood Smoke (clean Air Exposure)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2025-09-26 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06841913
The ClinicalTrials.gov registry entry for NCT06841913 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which LAIV nasal vaccine is chosen as a model viral infection is the first listed.
NCT06841913 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06841913 about?
NCT06841913 is a clinical study titled "Woodsmoke Exposure, Influenza Infection, and Nasal Immunity". This study will investigate the effects of woodsmoke (WS) exposure on human nasal mucosal immune responses to viral infection. The study tests the hypotheses that WS exposure modifies biomarkers of nasal mucosal immune function, increases in Live Attenuated Influenza Virus (LAIV) -induced nasal symp...
What is the current status of trial NCT06841913?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 112 participants. The study started on 2025-09-26. Estimated completion is 2028-12-31.
What interventions are being tested in trial NCT06841913?
The interventions under investigation include: LAIV nasal vaccine is chosen as a model viral infection (BIOLOGICAL), Wood smoke (OTHER), Placebo for LAIV nasal vaccine is chosen as a model viral infection (BIOLOGICAL), Placebo for Wood Smoke (clean Air Exposure) (OTHER).
Who is sponsoring clinical trial NCT06841913?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.